

USSN 09/521,696

Attorney Docket No. 22058-521 (GI5345)



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Keith et al.

SERIAL NUMBER: 09/521,696

EXAMINER: Jegatheesan  
Seharaseyon

FILING DATE: March 9, 2000

ART UNIT: 1647

FOR: USE OF INTERLEUKIN-11 TO PREVENT IMMUNE-MEDIATED CYTOTOXICITY


Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**Declaration of James C. Keith, Jr.**

I, James C. Keith, Jr., D.V.M., Ph.D., declare and state:

1. I am a joint inventor of the subject matter described and claimed in United States Patent Application Serial No. 09/521,696, filed March 9, 2000 ("the 696 application"), entitled "Use of Interleukin-11 to Prevent Immune-Mediated Cytotoxicity".
2. I am a co-author of the publication entitled "Interleukin-11 Promotes T Cell Polarization and Prevents Acute Graft-Versus-Host Disease after Allogenic Bone Marrow Transplantation," Journal of Clinical Investigation 102:, No. 1, pp. 115-123. The publication describes Applicant's own work to the extent it provides experimental details of a study that was performed as a result of Applicant's ideas.
3. The other authors on the publication, Geoffrey R. Hill, Kenneth R. Cooke, Takanori Teshima, James M. Crawford, Yani S. Brinson, David Bungard, and James L. M. Ferrara, are not co-inventors of the subject matter claimed in the present patent application.

4. I further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that willful false statements may jeopardize the validity of this application and any patent issuing therefrom.

  
James C. Keith, Jr., D.V.M., Ph.D

March 10, 2005  
Date